Arun Singavi
Hematology & Oncology · Chandler, AZNPI 1417222548
Payments from drug & device makers
Across 151 payments — averaging $172.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$11K
- Regeneron$4K
- AbbVie$3K
- Pharmacosmos Therapeutics Inc.$2K
- Incyte Corporation$1K
- Bayer$964
- plus $4K from 35 others
What the payments were for
- Consulting fees$20,49479%
- Speaking & faculty fees$1,5006%
- Travel & lodging$8073%
- Food & beverage$3,23212%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 18 | $11,102 |
| Regeneron | 4 | $3,969 |
| AbbVie | 18 | $2,899 |
| Pharmacosmos Therapeutics Inc. | 6 | $2,408 |
| Incyte Corporation | 2 | $1,121 |
| Bayer | 4 | $964 |
| Geron Corporation | 1 | $960 |
| AstraZeneca | 10 | $307 |
| Cardinal Health 110 LLC | 1 | $275 |
| Bristol Myers Squibb | 5 | $197 |
| E.r. Squibb & Sons, L.L.C. | 11 | $191 |
| Pfizer | 10 | $175 |
| Gilead | 6 | $123 |
| Medtronic | 1 | $121 |
| Novartis | 6 | $115 |
| Merck | 7 | $111 |
| Intuitive Surgical | 1 | $90 |
| GSK | 3 | $83 |
| Sobi, Inc | 4 | $79 |
| Johnson & Johnson | 4 | $67 |
| Springworks Therapeutics, Inc. | 3 | $59 |
| Progenics Pharmaceuticals, Inc. | 2 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Mirati Therapeutics, Inc. | 2 | $47 |
| Seagen Inc. | 2 | $46 |
| Astellas Pharma US Inc | 2 | $44 |
| Agios Pharmaceuticals, Inc. | 1 | $44 |
| Puma Biotechnology, Inc. | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $39 |
| Genmab U.S., Inc. | 1 | $33 |
| AVEO Pharmaceuticals, Inc. | 1 | $29 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| ADC Therapeutics America, Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $23 |
| Sanofi | 1 | $20 |
| Digestive Care, Inc. | 1 | $20 |
| Beigene USA, Inc. | 1 | $18 |
| Tempus AI, Inc | 1 | $13 |
| Acrotech Biopharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,045 in reported general payments places this provider in the 50th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 38 | $874,551 |
| EliquisApixaban | 258 | $291,435 |
| OrserduElacestrant Hcl | 12 | $278,093 |
| TagrissoOsimertinib Mesylate | 11 | $186,836 |
| ErivedgeVismodegib | 13 | $174,627 |
| Lenalidomide | 12 | $143,899 |
| XtandiEnzalutamide | 13 | $105,730 |
| XareltoRivaroxaban | 70 | $82,200 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 18 | $5,531 |
| Abiraterone Acetate | 44 | $5,519 |
| Anastrozole | 137 | $2,598 |
| Exemestane | 22 | $2,136 |
| Imatinib Mesylate | 26 | $2,110 |
| Ondansetron Hcl | 130 | $1,906 |
| Prochlorperazine Maleate | 83 | $1,515 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $191 | $874,55138 claims |
| PfizerEliquis | $175 | $291,435258 claims |
| AstraZenecaTagrisso | $307 | $186,83611 claims |
| Astellas Pharma US IncXtandi | $44 | $105,73013 claims |
| Johnson & JohnsonXarelto | $67 | $82,20070 claims |
| Lilly USA, LLCOlanzapine | $23 | $18828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Chandler
- Mikhail ShtivelbandChandler$9.1M
- Sujith KalmadiChandler$4.7M
- Tanios Bekaii-SaabScottsdale$31.4M
- Yousef ZakhariaScottsdale$13M
- Jiaxin NiuGilbert$10.7M
- Sudhir MandaTucson$10M
- Parminder SinghScottsdale$9.7M
- Michael GordonScottsdale$9.2M
- Daniel AhnScottsdale$9.1M
- Javier MunozPhoenix$8.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.